Lilly Reports Results of Trulicity (dulaglutide) in P-III AWARD-11 Study for Type 2 Diabetes

 Lilly Reports Results of Trulicity (dulaglutide) in P-III AWARD-11 Study for Type 2 Diabetes

Lilly Reports Results of Trulicity (dulaglutide) in P-III AWARD-11 Study for Type 2 Diabetes

Shots:

  • The P-III AWARD-11 study results involve assessing of Trulicity (3.0mg/4.5mg, qw) vs Trulicity (1.5mg, qw) in 1842 patients with type 2 diabetes for 52wks.
  • The P-III AWARD study resulted in meeting its 1EPs & 2EPs @36wks. i.e, superiority in A1C reduction & superiority on weight reduction with its expected completion in H2’19
  • Trulicity is a therapy used to improve blood sugar level in type 2 diabetes mellitus in adults along with diet & exercise with its expected regulatory submission in H2’19

Click here to read full press release/ article | Ref: Eli Lilly | Image: Fortune

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post